Roxana Cojocneanu-Petric

Dr. Roxana Cojocneanu-Petric


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
AIAlexandra-Iulia Irimie-Aghiorghiesei
Alexandra-Iulia Irimie-Aghiorghiesei
Cornelia BraicuCornelia Braicu
Cornelia Braicu
RCRoxana Cojocneanu-Petric
Roxana Cojocneanu-Petric
LMLorand Magdo
Lorand Magdo
AOAnca Onaciu
Anca Onaciu
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
Smoking is a well-known behavior that has an important negative impact on human health, and is considered to be a significant factor related to the development and progression of head and neck squamous cell carcinomas (HNSCCs). Use of high-dimensional datasets to discern novel HNSCC driver genes related to smoking represents an important challenge. The Cancer Genome Atlas (TCGA) analysis was performed in three co-existing groups of HNSCC in order to assess whether gene expression landscape is affected by tobacco smoking, having quit, or non-smoking status. We identified a set of differentially expressed genes that discriminate between smokers and non-smokers or based on human papilloma virus (HPV)16 status, or the co-occurrence of these two exposome components in HNSCC. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways classification shows that most of the genes are specific to cellular metabolism, emphasizing metabolic detoxification pathways, metabolism of chemical carcinogenesis, or drug metabolism. In the case of HPV16-positive patients it has been demonstrated that the altered genes are related to cellular adhesion and inflammation. The correlation between smoking and the survival rate was not statistically significant. This emphasizes the importance of the complex environmental exposure and genetic factors in order to establish prevention assays and personalized care system for HNSCC, with the potential for being extended to other cancer types.

22 July 2015 in Medicine and Pharmacy Reports
Verified
Journal Article
Open access
PDF file
RCRoxana Cojocneanu-Petric
Roxana Cojocneanu-Petric
LPLaura-Ancuta Pop
Laura-Ancuta Pop
AJAncuta Jurj
Ancuta Jurj
Lajos-Zsolt RadulyLajos-Zsolt Raduly
Lajos-Zsolt Raduly
DDDan Dumitrascu
Dan Dumitrascu
INIoana Berindan Neagoe
Ioana Berindan Neagoe
For some time, cancer has not been thought of as a disease, but as a multifaceted, heterogeneous complex of genotypic and phenotypic manifestations leading to tumorigenesis. Due to recent technological progress, the outcome of cancer patients can be greatly improved by introducing in clinical practice the advantages brought about by the development of next generation sequencing techniques. Biomedical suppliers have come up with various applications which medical researchers can use to characterize a patient’s disease from molecular and genetic point of view in order to provide caregivers with rapid and relevant information to guide them in choosing the most appropriate course of treatment, with maximum efficiency and minimal side effects. Breast cancer, whose incidence has risen dramatically, is a good candidate for these novel diagnosis and therapeutic approaches, particularly when referring to specific sequencing panels which are designed to detect germline or somatic mutations in genes that are involved in breast cancer tumorigenesis and progression. Benchtop next generation sequencing machines are becoming a more common presence in the clinical setting, empowering physicians to better treat their patients, by offering early diagnosis alternatives, targeted remedies, and bringing medicine a step closer to achieving its ultimate goal, personalized therapy.